Pages that link to "Q43035611"
Jump to navigation
Jump to search
The following pages link to Perspectives: towards a peptide-based vaccine against hepatitis C virus. (Q43035611):
Displaying 27 items.
- Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin (Q30361736) (← links)
- Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs. (Q30843134) (← links)
- Recent progress in adjuvant discovery for peptide-based subunit vaccines (Q34033780) (← links)
- In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitiz (Q34520887) (← links)
- Hepatitis C: molecular virology and antiviral targets (Q34970582) (← links)
- New technology platforms in the development of vaccines for the future (Q35023493) (← links)
- Population of the HLA ligand database (Q35080071) (← links)
- Hepatitis vaccines: recent advances (Q35143274) (← links)
- Virosomal adjuvanted antigen delivery systems (Q35192175) (← links)
- Developments in hepatitis C therapy during 2000 – 2002 (Q35581123) (← links)
- Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. (Q35588125) (← links)
- Recent developments in target identification against hepatitis C virus (Q35842500) (← links)
- Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations (Q36968260) (← links)
- Virus-like particle vaccines and adjuvants: the HPV paradigm (Q37608311) (← links)
- Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens (Q37812128) (← links)
- Current strategies for subunit and genetic viral veterinary vaccine development. (Q37840709) (← links)
- Influenza virosomes as a vaccine adjuvant and carrier system (Q37867100) (← links)
- Influenza virosomes as vaccine adjuvant and carrier system (Q38124062) (← links)
- Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient (Q40724021) (← links)
- Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV-infected individuals without HLA-A2 restriction (Q42986524) (← links)
- Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition (Q42999608) (← links)
- Serum levels of IgG to the peptide of HCV1b core at positions 35-44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132-2140 correlated with better prognosis in HCV-infected patients (Q43038542) (← links)
- Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy (Q43040590) (← links)
- Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b(+) HLA-A24(+) patients (Q44521320) (← links)
- Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. (Q45418238) (← links)
- Viral crosstalk: who gets to say what first? (Q74173808) (← links)
- [Immunisation: leaps into the future. Viral hepatitis] (Q78503327) (← links)